Home
About
Leadership
Medical Advisory Board (AC5)
Scientific & Clinical Advisors
Corporate Mission
Products
Ordering Information
Intellectual Property
AC5 Advanced Wound System
Technology
Platform
Preclinical Data
Clinical Data
Pipeline
Pipeline Opportunity
Investors
Investor Relations
IR Overview
News
Press Releases
IR Calendar
Presentations
Other News
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Governance Documents
Contact
Home
Investors
News
Press Releases
Investors
Overview
News
Press Releases
IR Calendar
Presentations
Other News
Stock Data
SEC Filings
Corporate Governance
Press Releases
All News
By Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
11/28/18
Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe
11/26/18
Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018
10/1/18
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel
09/25/18
Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018
09/5/18
Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
08/28/18
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018
08/16/18
Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018
07/20/18
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
06/29/18
Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering
06/26/18
Arch Therapeutics Provides Skin Sensitization Study Status Update
<< Previous
1...
5
6
7
8
9
10
11
12
13
14
Next >>
Show All